United States Daily Briefing

S&P 500 companies are on track for their strongest earnings in five years, per the FT — and Amazon's +15.3% move today is the embodiment of that. The consumer-discretionary giant's results reinforced the thesis that top-line demand is healthy and that AI-infrastructure investment is flowing directly to the cloud hyperscalers. The knock-on: NASDAQ-heavy ETFs and sector names like Shopify, Wayfair, and AMZN-logistics peers are all re-rated on expectations of renewed consumer wallet-share gains.

Italian cable giant Prysmian is in advanced talks to acquire US electrical manufacturer Atkore Inc., according to LiveMint. The deal would mark a significant cross-Atlantic M&A move in the electrical infrastructure space — a sector getting fresh attention from US grid-hardening and energy transition capex cycles. Atkore's premium market position in electrical conduit and cable management systems makes it a logical target as infrastructure investment accelerates. Watch for competing bids and regulatory review timelines in this sector.

Bloomberg confirmed AstraZeneca held discussions with Bristol Myers Squibb on a potential $400bn merger — what would be one of the largest pharmaceutical deals ever. AZN's ambition signals that the post-Celgene pharma consolidation wave has not yet peaked. For US healthcare investors, this re-prices M&A optionality across large-cap pharma: AbbVie, Pfizer, and Sanofi all benefit from a rising tide of deal activity as payers, not just patients, become the key negotiating variable in biopharma valuations.